Please check your internet connection and try again.
# Potassium Chloride
## Overview
Potassium chloride (KCl) is an essential electrolyte used to treat or prevent hypokalemia. It is available in oral and intravenous formulations.
## Primary Indications
* Treatment of hypokalemia (serum potassium < 3.5 mEq/L).
* Prevention of hypokalemia in patients at risk.
## Adult Dosing
* **Oral:**
* Prevention: 20 mEq/day.
* Treatment: 40-100 mEq/day divided into 2-5 doses.
* Maximum single oral dose: 20 mEq (for immediate-release formulations). Higher doses may be used under close monitoring.
* **Intravenous (IV):**
* Treatment of symptomatic hypokalemia or serum potassium < 2.5 mEq/L: Typically 10-20 mEq/hour, infused centrally.
* Maximum infusion rate: Generally 10 mEq/hour for peripheral administration; up to 20 mEq/hour (or higher in critical situations) centrally with continuous ECG monitoring.
* Maximum single IV dose: 40 mEq (standard concentrations). Higher doses may be administered in life-threatening situations, requiring critical care and continuous cardiac monitoring.
* *Specific IV dosing and infusion rates may vary based on local protocols and patient condition.*
## Pediatric Dosing
* **Oral:**
* Prevention: 1-2 mEq/kg/day, not to exceed 20 mEq/day.
* Treatment: 2-5 mEq/kg/day, not to exceed 40 mEq/day, divided into 2-4 doses.
* **Intravenous (IV):**
* Treatment: 0.5-1 mEq/kg per dose, infused at a maximum rate of 10 mEq/hour.
* Maximum daily dose: Generally 20 mEq/kg/day or 300 mEq/day, whichever is less.
* *Extreme caution and continuous ECG monitoring are required for IV potassium administration in children, especially at higher concentrations or rates.*
## Dose Adjustments
* Dose should be adjusted based on serum potassium levels, clinical response, and acid-base status.
* Renal impairment: Use with caution; dose reduction may be necessary. Monitor potassium closely.
## Contraindications
* Hyperkalemia (serum potassium > 5.0 mEq/L).
* Conditions causing increased potassium levels, such as severe renal impairment, untreated Addison's disease, or acute dehydration.
* Certain diuretic therapies (e.g., potassium-sparing diuretics) may require adjustment or avoidance.
## Adverse Effects
* **Most common:** Nausea, vomiting, diarrhea, abdominal pain (oral).
* **Serious:** Hyperkalemia (especially with rapid IV infusion or in renal impairment), cardiac arrhythmias, ECG changes, cardiac arrest.
* Irritation or phlebitis at IV site.
## Key Drug Interactions
* **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia.
* **ACE inhibitors, Angiotensin Receptor Blockers (ARBs), NSAIDs, Heparin:** Can increase serum potassium, increasing risk of hyperkalemia.
* **Digitalis glycosides:** Hyperkalemia can potentiate digitalis toxicity. Hypokalemia can increase digitalis toxicity.
* **Neuromuscular blocking agents:** Potassium can affect neuromuscular transmission.
## Monitoring
* Serum potassium levels (frequently, especially during IV therapy or dose changes).
* Renal function (BUN, creatinine).
* ECG (especially during rapid IV infusion or if clinical signs of hyperkalemia are present).
* Fluid balance and urine output.
* Signs and symptoms of hypokalemia and hyperkalemia.
## Clinical Pearls
* Oral potassium supplements should be taken with food or a meal to minimize gastrointestinal upset.
* Dilute IV potassium solutions appropriately to prevent vein irritation and phlebitis. Avoid bolus administration.
* Always ensure adequate urine output before administering potassium.
* Symptoms of hyperkalemia include muscle weakness, paresthesias, bradycardia, and ECG changes.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult current prescribing information and institutional guidelines for complete details and to confirm dosages and safety information.
